[{"id":"bf5cc737-c6cb-4899-99a5-c61a24a807ae","acronym":"SJ901","url":"https://clinicaltrials.gov/study/NCT04923126","created_at":"2021-06-11T18:56:10.986Z","updated_at":"2025-02-25T12:37:53.246Z","phase":"Phase 1/2","brief_title":"SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma","source_id_and_acronym":"NCT04923126 - SJ901","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" BRAF • NF1 • PTPN11 • MYBL1","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • NF1 • PTPN11 • MYBL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 06/21/2021","start_date":" 06/21/2021","primary_txt":" Primary completion: 06/01/2031","primary_completion_date":" 06/01/2031","study_txt":" Completion: 06/01/2031","study_completion_date":" 06/01/2031","last_update_posted":"2025-02-24"},{"id":"f34327ea-f002-4122-8c11-9595b9888d7d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05578092","created_at":"2022-10-13T17:58:11.601Z","updated_at":"2025-02-25T13:49:34.674Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway","source_id_and_acronym":"NCT05578092","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" EGFR • KRAS • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12","tags":["EGFR • KRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • MRTX0902"],"overall_status":"Recruiting","enrollment":" Enrollment 228","initiation":"Initiation: 12/02/2022","start_date":" 12/02/2022","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 07/30/2026","study_completion_date":" 07/30/2026","last_update_posted":"2025-02-21"},{"id":"f2c492b8-d008-47fb-bfe0-8880113c29ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT06113289","created_at":"2023-11-02T15:12:40.366Z","updated_at":"2025-02-25T15:21:01.496Z","phase":"Phase 1/2","brief_title":"A Phase 1B/2A Trial of Combination of ASTX727 with ASTX029 in Acute Myeloid Leukemia","source_id_and_acronym":"NCT06113289","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • NF1 • PTPN11","pipe":"","alterations":" ","tags":["KRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • beroterkib anhydrous (ASTX029)"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 02/08/2024","start_date":" 02/08/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-12"},{"id":"77cb581e-c173-4f2c-a06e-c96db7736264","acronym":"RAS-HEMATO","url":"https://clinicaltrials.gov/study/NCT04286360","created_at":"2021-01-18T20:48:27.393Z","updated_at":"2024-07-02T16:34:59.177Z","phase":"","brief_title":"Hematological Anomalies in Children With Rasopathy","source_id_and_acronym":"NCT04286360 - RAS-HEMATO","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • PTPN11 • MAP2K2 • RAF1 • RIT1 • LZTR1","pipe":" | ","alterations":" BRAF mutation • CBL mutation • MAP2K1 mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • PTPN11 • MAP2K2 • RAF1 • RIT1 • LZTR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • CBL mutation • MAP2K1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/11/2020","start_date":" 11/11/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 11/01/2029","study_completion_date":" 11/01/2029","last_update_posted":"2024-06-04"},{"id":"02eaf617-0513-44fc-bea7-b3c0c01ecd8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05849662","created_at":"2023-05-09T14:04:18.433Z","updated_at":"2024-07-02T16:35:02.520Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia","source_id_and_acronym":"NCT05849662","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" KRAS • NRAS • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation","tags":["KRAS • NRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • cytarabine • azacitidine • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 05/10/2024","start_date":" 05/10/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-20"},{"id":"3b52b9d4-20d4-4a79-a816-f21eb9b91b3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807932","created_at":"2023-04-11T14:03:36.196Z","updated_at":"2024-07-02T16:35:06.548Z","phase":"Phase 1/2","brief_title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","source_id_and_acronym":"NCT05807932","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" KRAS • TP53 • NRAS • IDH1 • IDH2 • NF1 • RUNX1 • KMT2A • PTPN11 • NUP214 • DEK • RIT1","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • CBL mutation","tags":["KRAS • TP53 • NRAS • IDH1 • IDH2 • NF1 • RUNX1 • KMT2A • PTPN11 • NUP214 • DEK • RIT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • fludarabine IV • Grafapex (treosulfan) • Amsidine (amsacrine)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/30/2028","study_completion_date":" 01/30/2028","last_update_posted":"2024-05-01"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"b4509b46-cf96-4a36-af86-5a28202e4c9b","acronym":"CONCERTO","url":"https://clinicaltrials.gov/study/NCT04409639","created_at":"2021-01-18T21:15:48.018Z","updated_at":"2024-07-02T16:35:17.291Z","phase":"Phase 2","brief_title":"Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations","source_id_and_acronym":"NCT04409639 - CONCERTO","lead_sponsor":"University of Utah","biomarkers":" KRAS • BRAF • FLT3 • NRAS • NF1 • JAK2 • PTPN11","pipe":" | ","alterations":" BRAF mutation • NF1 mutation","tags":["KRAS • BRAF • FLT3 • NRAS • NF1 • JAK2 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 01/12/2021","start_date":" 01/12/2021","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2026","study_completion_date":" 08/15/2026","last_update_posted":"2024-02-28"},{"id":"d6f097ba-9519-4376-8dfc-112499960700","acronym":"","url":"https://clinicaltrials.gov/study/NCT02840409","created_at":"2021-01-18T13:56:34.086Z","updated_at":"2024-07-02T16:35:21.598Z","phase":"Phase 2","brief_title":"Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)","source_id_and_acronym":"NCT02840409","lead_sponsor":"The Hospital for Sick Children","biomarkers":" BRAF • FGFR1 • NTRK2 • NF1 • PTPN11 • ATRX • RAF1 • H3-3A • MYBL1","pipe":" | ","alterations":" BRAF mutation • FGFR1 fusion","tags":["BRAF • FGFR1 • NTRK2 • NF1 • PTPN11 • ATRX • RAF1 • H3-3A • MYBL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • FGFR1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • vinblastine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-01-31"},{"id":"0f841029-f2ce-4cb1-849c-75709569b46f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03613532","created_at":"2021-03-05T16:52:31.672Z","updated_at":"2024-07-02T16:35:22.047Z","phase":"Phase 1","brief_title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","source_id_and_acronym":"NCT03613532","lead_sponsor":"Jacqueline Garcia, MD","biomarkers":" KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type","tags":["KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-26"},{"id":"04cc697b-a936-4795-aed4-1231c763328e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441514","created_at":"2022-07-01T20:56:41.287Z","updated_at":"2024-07-02T16:35:25.985Z","phase":"Phase 1","brief_title":"Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05441514","lead_sponsor":"City of Hope Medical Center","biomarkers":" KRAS • BRAF • NRAS • IDH2 • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • IDH2 mutation • NF1 mutation • RAS mutation • CBL mutation • IDH2 R140 • IDH2 R172","tags":["KRAS • BRAF • NRAS • IDH2 • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • IDH2 mutation • NF1 mutation • RAS mutation • CBL mutation • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 05/02/2025","study_completion_date":" 05/02/2025","last_update_posted":"2023-12-18"},{"id":"a6aad9f1-0518-4d3b-a71b-32706868cb46","acronym":"ADVL1521","url":"https://clinicaltrials.gov/study/NCT03190915","created_at":"2021-01-18T15:44:00.418Z","updated_at":"2024-07-02T16:35:29.990Z","phase":"Phase 2","brief_title":"Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia","source_id_and_acronym":"NCT03190915 - ADVL1521","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1 • PTPN11","pipe":" | ","alterations":" NF1 mutation • RAS mutation • PTPN11 mutation • CBL mutation","tags":["NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation • RAS mutation • PTPN11 mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/09/2018","start_date":" 09/09/2018","primary_txt":" Primary completion: 03/31/2023","primary_completion_date":" 03/31/2023","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-11-08"},{"id":"0f0b0890-fa2b-48fb-a929-8a1bc66f161c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06104488","created_at":"2023-10-27T17:14:00.798Z","updated_at":"2024-07-02T16:35:31.349Z","phase":"Phase 1","brief_title":"A Study of Avutometinib for People With Solid Tumor Cancers","source_id_and_acronym":"NCT06104488","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" KRAS • NRAS • HRAS • NF1 • PTPN11","pipe":" | ","alterations":" NF1 mutation","tags":["KRAS • NRAS • HRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/20/2023","start_date":" 10/20/2023","primary_txt":" Primary completion: 10/20/2029","primary_completion_date":" 10/20/2029","study_txt":" Completion: 10/20/2029","study_completion_date":" 10/20/2029","last_update_posted":"2023-10-27"},{"id":"7de7e1ee-5af6-45a1-8fb5-cc69121b84de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04487106","created_at":"2021-01-18T21:32:24.763Z","updated_at":"2024-07-02T16:35:53.866Z","phase":"Phase 2","brief_title":"Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT04487106","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • NRAS • KIT • HRAS • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • KIT mutation • NF1 mutation • HRAS mutation • CBL mutation","tags":["KRAS • BRAF • NRAS • KIT • HRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • KIT mutation • NF1 mutation • HRAS mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Mekinist (trametinib) • azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 07/21/2020","start_date":" 07/21/2020","primary_txt":" Primary completion: 02/09/2023","primary_completion_date":" 02/09/2023","study_txt":" Completion: 02/09/2023","study_completion_date":" 02/09/2023","last_update_posted":"2023-03-07"},{"id":"ec19f33b-7b3a-4da5-8e6a-47575a751dbe","acronym":"HEM-iSMART D","url":"https://clinicaltrials.gov/study/NCT05658640","created_at":"2022-12-21T15:59:05.726Z","updated_at":"2024-07-02T16:35:58.797Z","phase":"Phase 1/2","brief_title":"HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies","source_id_and_acronym":"NCT05658640 - HEM-iSMART D","lead_sponsor":"Princess Maxima Center for Pediatric Oncology","biomarkers":" FLT3 • NRAS • HRAS • MAP2K1 • NF1 • PTPN11","pipe":" | ","alterations":" NF1 mutation","tags":["FLT3 • NRAS • HRAS • MAP2K1 • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • cytarabine • cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 04/01/2029","primary_completion_date":" 04/01/2029","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2022-12-21"},{"id":"f70ef90a-fdc9-405b-b396-50a810ed6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05273099","created_at":"2022-03-10T14:58:06.191Z","updated_at":"2024-07-02T16:36:13.173Z","phase":"","brief_title":"Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma","source_id_and_acronym":"NCT05273099","lead_sponsor":"Università degli Studi di Ferrara","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A","pipe":" | ","alterations":" JAK3 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-12"},{"id":"73e97b9d-0254-43f8-997d-ea880735e4cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT03311815","created_at":"2021-01-18T16:21:28.250Z","updated_at":"2024-07-02T16:36:34.554Z","phase":"","brief_title":"Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.","source_id_and_acronym":"NCT03311815","lead_sponsor":"PETHEMA Foundation","biomarkers":" KRAS • TP53 • FLT3 • NRAS • IDH1 • IDH2 • NPM1 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • PTPN11 • SRSF2 • WT1 • U2AF1 • CEBPA • SETBP1 • GATA2","pipe":" | ","alterations":" U2AF1 mutation","tags":["KRAS • TP53 • FLT3 • NRAS • IDH1 • IDH2 • NPM1 • DNMT3A • JAK2 • RUNX1 • SF3B1 • ASXL1 • TET2 • PTPN11 • SRSF2 • WT1 • U2AF1 • CEBPA • SETBP1 • GATA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e U2AF1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 900","initiation":"Initiation: 10/06/2017","start_date":" 10/06/2017","primary_txt":" Primary completion: 10/15/2019","primary_completion_date":" 10/15/2019","study_txt":" Completion: 10/15/2019","study_completion_date":" 10/15/2019","last_update_posted":"2021-02-16"},{"id":"bf75e380-cf06-45ab-9526-c6dc47a6700e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04505995","created_at":"2021-01-18T21:36:19.252Z","updated_at":"2024-07-02T16:36:42.207Z","phase":"","brief_title":"Azacitidine and Homoharringtonine in JMML","source_id_and_acronym":"NCT04505995","lead_sponsor":"Fourth Military Medical University","biomarkers":" KRAS • NRAS • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • PTPN11 mutation","tags":["KRAS • NRAS • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • PTPN11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Synribo (omacetaxine mepesuccinate)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/01/2020","start_date":" 01/01/2020","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2020-08-10"},{"id":"d582e599-215d-4eb6-8b2c-a2836eb99b24","acronym":"","url":"https://clinicaltrials.gov/study/NCT02447666","created_at":"2021-01-18T11:43:49.376Z","updated_at":"2024-07-02T16:36:58.220Z","phase":"Phase 2","brief_title":"Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)","source_id_and_acronym":"NCT02447666","lead_sponsor":"Celgene","biomarkers":" KRAS • NRAS • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • PTPN11 mutation","tags":["KRAS • NRAS • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • PTPN11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/15/2015","start_date":" 09/15/2015","primary_txt":" Primary completion: 02/28/2018","primary_completion_date":" 02/28/2018","study_txt":" Completion: 05/24/2019","study_completion_date":" 05/24/2019","last_update_posted":"2019-07-11"}]